Grepafloxacin: Difference between revisions
m (Protected "Grepafloxacin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 19: | Line 19: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Grepafloxacin hydrochloride''' (Raxar®, [[Glaxo Wellcome]]) is an oral broad-spectrum [[quinoline]] [[antibacterial]] agent used to treat [[bacteria]]l [[infection]]s. Grepafloxacin was withdrawn in the [[United States]] due to its side effect of lengthening the [[QT interval]] on the [[electrocardiogram]], leading to cardiac events and [[sudden death]]. | '''Grepafloxacin hydrochloride''' (Raxar®, [[Glaxo Wellcome]]) is an oral broad-spectrum [[quinoline]] [[antibacterial]] agent used to treat [[bacteria]]l [[infection]]s. Grepafloxacin was withdrawn in the [[United States]] due to its side effect of lengthening the [[QT interval]] on the [[electrocardiogram]], leading to cardiac events and [[sudden death]]. | ||
| Line 29: | Line 29: | ||
[[th:เกรพพาฟลอกซาซิน]] | [[th:เกรพพาฟลอกซาซิน]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 15:40, 9 August 2012
| File:Grepafloxacin.svg | |
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 50% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C19H22FN3O3 |
| Molar mass | 359.395 g/mol |
|
WikiDoc Resources for Grepafloxacin |
|
Articles |
|---|
|
Most recent articles on Grepafloxacin Most cited articles on Grepafloxacin |
|
Media |
|
Powerpoint slides on Grepafloxacin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Grepafloxacin at Clinical Trials.gov Trial results on Grepafloxacin Clinical Trials on Grepafloxacin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Grepafloxacin NICE Guidance on Grepafloxacin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Grepafloxacin Discussion groups on Grepafloxacin Patient Handouts on Grepafloxacin Directions to Hospitals Treating Grepafloxacin Risk calculators and risk factors for Grepafloxacin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Grepafloxacin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Grepafloxacin hydrochloride (Raxar®, Glaxo Wellcome) is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Grepafloxacin was withdrawn in the United States due to its side effect of lengthening the QT interval on the electrocardiogram, leading to cardiac events and sudden death.
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Fluoroquinolone antibiotics
- Withdrawn drugs